The lead compound, as well as conformation-sensitive antibodies, specifically interacts with an oxidized conformer of MIF (oxMIF) enriched in postmortem brain homogenates of patients with Alzheimer's disease (AD). Here, MIF is linked to early-onset autosomal dominant Alzheimer disease.